FTA to batter generic drug business and raise patent disputes.

It is expected that the KORUS FTA settlement may raise a lot of patent disputes between the original drug companies and generic drug manufacturers, and if any patent lawsuit be raised, its copy drug registration may be decided to cancel at the KFDA within one year after its file.

The recognition of exclusive rights kept by the original drug owner for their registration data may give a serio...